SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer

Authors:
  • HCH. Chung
    H. Chung
  • KLK. Lee
    K. Lee
  • WKW. Kim
    W. Kim
  • JGJ. Gainor
    J. Gainor
  • NLN. Lakhani
    N. Lakhani
  • LCL. Chow
    L. Chow
  • WMW. Messersmith
    W. Messersmith
  • PFP. Fanning
    P. Fanning
  • PSP. Squifflet
    P. Squifflet
  • FJF. Jin
    F. Jin
  • AFA. Forgie
    A. Forgie
  • HWH. Wan
    H. Wan

Abstract
No abstract available